nach oben

Reactions Weekly

Erschienen in:

01.06.2023 | Case report

Afatinib/cisplatin/gemcitabine

Acquired resistance and lack of efficacy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is&colon;

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Baglivo S, et al. Inflamed Tumor Phenotype as Predictor of Long-Term Response to Pembrolizumab in an EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Patient with Acquired Resistance to Afatinib: a Case Report and Review of the Literature. Oncology and Therapy 10: 291-300, No. 1, Jun 2022. Available from: URL: http://www.springer.com/springer+healthcare/journal/40487

Titel: Afatinib/cisplatin/gemcitabine
Acquired resistance and lack of efficacy: case report
Publikationsdatum: 01.06.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-41688-z

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Afatinib/cisplatin/gemcitabine

Acquired resistance and lack of efficacy: case report

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Amoxicillin/clarithromycin/omeprazole

Azathioprine/ciclosporin/infliximab

Vismodegib

Methylprednisolone/mycophenolate/tacrolimus

Clonazepam/corticotropin

Methylprednisolone/propylthiouracil